Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 11Thoracic 5Sarcoma 3Lymphoid 3Tumor-Agnostic 1Gynecologic 1

Conditions

Hodgkin Disease 3Recurrence 1

Interventions

Cyclophosphamide 166Rituximab 153Specimen Handling 111Biopsy 89Magnetic Resonance Spectroscopy 87Vincristine 85Doxorubicin 79Prednisone 78fludarabine 68venetoclax 65obinutuzumab 60ibrutinib 54Lenalidomide 53Dexamethasone 53Cytarabine 47Methotrexate 44acalabrutinib 42Etoposide 41CT-P10 39blinatumomab 38Bendamustine Hydrochloride 34fludarabine phosphate 33prednylidene 32Gemcitabine 32deltacortene 31Calcium Dobesilate 30zanubrutinib 29pembrolizumab 29glofitamab 27Nivolumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Vinorelbine × Lymphoid × 90 days × Clear all
NCT07021989 2026-06-04

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

University of California, San Francisco

Phase 2 Not yet recruiting
38 enrolled
Lymphoid

Hodgkin Disease

NCT06377566 2026-04-23

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
71 enrolled
Lymphoid

Hodgkin Disease

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
257 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡